Physician profile
Kai Ming Fu
NPI 1104033349
$155,882.21
in general payments reported to CMS, 2019-2025
24 companies · $5,393 in 2025
The $5,393 reported for 2025 was more than what 81% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $13K · 2021: $24K · 2022: $17K · 2023: $34K · 2024: $19K · 2025: $5,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $5,561 · Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,952.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Travel and Lodging | $5,560.94 |
| Food and Beverage | $2,958.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $37,783.59 | 2019-2024 | Skyline |
| Alphatec Spine, INC | $30,570.21 | 2021-2024 | Other - Miscellaneous, Identiti, Battalion Tlif - PC |
| Globus Medical, INC. | $19,274.10 | 2019-2025 | Excelsius Gps |
| Depuy Synthes Products, INC. | $14,298.98 | 2020-2024 | |
| Si-Bone, INC. | $12,978.77 | 2019-2022 | |
| Bioventus LLC | $11,355.50 | 2023-2025 | Bonescalpel, Bonescalpel & Sonicone (O.R.), Nexus-10 Mkii |
| Stryker Corporation | $9,001.92 | 2019-2025 | Xia 3, Everest Spinal System, Yukon Oct Spinal System |
| Medtronic, INC. | $7,132.32 | 2021 | |
| Cerapedics INC. | $5,504.20 | 2021-2022 | |
| Atlas Spine, INC. | $1,734.88 | 2019-2020 | |
| Depuy Synthes Sales INC. | $1,490.51 | 2019-2025 | Symphony, Teligen, Expedium Verse |
| Integrity Implants INC. Dba Accelus | $1,473.00 | 2023-2024 | |
| Integrity Implants INC. | $1,000.00 | 2022 | |
| 4web, INC. | $809.01 | 2019-2025 | Spine Truss System |
| Expanding Innovations, INC. | $599.00 | 2024 | X-Pac |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $197.61 | 2023 | |
| Medtronic USA, INC. | $187.92 | 2019-2020 | |
| Spineology INC. | $157.50 | 2019 | |
| Biocomposites INC | $85.74 | 2024 | |
| Nevro Corp. | $85.04 | 2022-2024 | Senza |
| Lifenet Health | $69.69 | 2025 | Pliafx Flo |
| Gs Solutions, INC. | $65.29 | 2024 | |
| Orthofix Medical, INC. | $15.78 | 2020 | |
| Misonix INC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,797.90 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Ming Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.